Preclinical describes every stage of research that precedes administration of a compound to humans. In the regulatory sense it names the package assembled to support an Investigational New Drug application: in vitro pharmacology and selectivity screening, in vivo efficacy in disease models, ADME and pharmacokinetics, safety pharmacology on cardiovascular, respiratory and CNS endpoints, and GLP toxicology in usually two species.
Why the word matters on a research-peptide site
Almost every peptide sold for research sits at this stage, and much of it sits at the earliest part of it — published rodent studies and cell work, without formal GLP toxicology or an IND. Saying "preclinical evidence exists" is therefore a precise and honest claim, and it is materially weaker than saying human trial data exist. Attrition rates make the distinction concrete: the large majority of compounds with encouraging animal data fail on efficacy or safety once tested in people, and translation from rodent models is the acknowledged bottleneck.
Reading practice follows: state the model, the species and the study type whenever citing a finding. "A rodent study reported" and "a phase 2 trial reported" are not interchangeable, and neither supports statements about outcomes in people using research-grade material, which is supplied for laboratory use only.
Related terms and material
phase 1/2/3 trial · FDA-approved vs research-grade. Reference material: all research products. Further reading: what research use only means.